Open human genome data - presentation at the annual TKT/CLIDP doctoral programme symposium 2016 "Open up! – Open Data and Open Access" of the University of Turku.
This document discusses genetic genealogy and DNA testing. It begins with definitions of genetic genealogy and traditional genealogy research. It then provides details on human genetics such as the number of chromosomes, genes, and single nucleotide polymorphisms (SNPs). The document lists some major DNA testing companies and notes that the consumer genomics market is growing rapidly. It discusses factors to consider when choosing a DNA testing company. The remainder provides information on genetic genealogy projects and the Gene by Gene laboratory.
The document discusses recent findings in ancient DNA research. It summarizes a 2014 Nature article that analyzed ancient human genomes from present-day Europeans and suggested three ancestral populations. It also lists 27 other relevant published ancient DNA studies from the past few years. Key criteria for evaluating the reliability of ancient DNA analyses are discussed, such as the journal and researchers involved, sample handling, contamination controls, and consistency of results.
Proteomics is the large-scale study of proteins. The document provides an overview of the history and concepts of proteomics, including definitions of key terms, descriptions of pioneering scientists and techniques, and the importance of bioinformatics in proteomics research. It discusses how proteomics has evolved from protein sequencing and gel electrophoresis to modern mass spectrometry-based techniques and quantitative analysis. The increasing role of proteomics in fields like structural biology and clinical applications is also noted.
This document discusses genetic genealogy and DNA testing. It begins with definitions of genetic genealogy and traditional genealogy research. It then provides details on human genetics such as the number of chromosomes, genes, and single nucleotide polymorphisms (SNPs). The document lists some major DNA testing companies and notes that the consumer genomics market is growing rapidly. It discusses factors to consider when choosing a DNA testing company. The remainder provides information on genetic genealogy projects and the Gene by Gene laboratory.
The document discusses recent findings in ancient DNA research. It summarizes a 2014 Nature article that analyzed ancient human genomes from present-day Europeans and suggested three ancestral populations. It also lists 27 other relevant published ancient DNA studies from the past few years. Key criteria for evaluating the reliability of ancient DNA analyses are discussed, such as the journal and researchers involved, sample handling, contamination controls, and consistency of results.
Proteomics is the large-scale study of proteins. The document provides an overview of the history and concepts of proteomics, including definitions of key terms, descriptions of pioneering scientists and techniques, and the importance of bioinformatics in proteomics research. It discusses how proteomics has evolved from protein sequencing and gel electrophoresis to modern mass spectrometry-based techniques and quantitative analysis. The increasing role of proteomics in fields like structural biology and clinical applications is also noted.
Festival of Genomics 2016 London: Challenges of Big Medical Data?Matthieu Schapranow
This presentation covers the "Challenges of Big Medical Data" presentation of the 2016 Festival of Genomics workshop "Big Medical Data in Precision Medicine: Challenges or Opportunities?" on Jan 19, 2016 in London.
With recent advances in Healthcare, Personalized medicine has become a buzzword. The customization of health care, based on DNA sequencing, patient's environmental information, can lead to more efficient treatments.
By integrating various sources of data, personalized medicine improves all aspects of healthcare from prevention to monitoring.
Searching for Clinical Trials using clinicaltrials.gov and specialized search
engines
Rob Camp goes through various online tools and search engines which enable
patients to search for clinical trials. Rob’s background includes serving as
Executive Director of the EATG (European AIDS Treatment Group), the creation
of an HIV organisation in Barcelona, the creation of national groups in Spain
and other countries (organising seminars on how to create organisations in EU
Eastern States, Southern States), leading projects supported by the European
Commission department for Public Health (DG SANCO), working on funding for
NGOs. Rob is currently working half time in the US as liaison between patient
organisations and the FDA, and spends the rest of his time in Europe. Rob
speaks English and Spanish
Presentation "The Impact of All Data on Healthcare"
Keith Perry
Associate VP & Deputy CIO
UT MD Anderson Cancer Center
With continuing advancement in both technology and medicine, the drive is on to make all data meaningful to drive medical discovery and create actionable outcomes. With tools and capabilities to capture more data than ever before, the challenge becomes linking existing structured and unstructured clinical data with genomic data to increase the industry’s analytical footprint.
Learning Objectives:
∙ Discuss the need to make all data meaningful in order to speed discovery of new knowledge
∙ Provide examples of an analytical direction that supports evolution in medicine
∙ Expose the challenges facing the industry with respect to ~omits
20160811 Big Data for Health and MedicineBrian Bot
This document summarizes Brian Bot's presentation on biomedical research in an increasingly digital world. It discusses how biomedical data is increasingly being produced, aggregated, and shared digitally. Only a small percentage of studies can be fully reproduced due to issues with data availability and documentation. However, organizations like Sage Bionetworks are working to promote open sharing of complex biological data through diverse collaborations and by empowering citizens to contribute their own health data to research. One example is the mPower study on Parkinson's disease which has involved thousands of participants sharing passive and active data through mobile apps.
This document outlines Atul Butte's conflicts of interest and support network. It lists his advisory roles and consulting for various pharmaceutical and technology companies. It also lists the research collaborations and institutional support he receives from UCSF, NIH, and other foundations. The document emphasizes building the strongest team in medical data analytics to predict disease, explain rare conditions, find new drugs, and ensure the right care for patients through analyzing large biomedical datasets.
This document discusses how analyzing the large amounts of data being generated from biomedical research can help discover new drugs and diagnostics. Specifically:
- There are now over 300 billion points of data available from sources like gene expression studies and clinical trials. This amount doubles every few years.
- By analyzing relationships within this large biomedical data, researchers have already identified new uses for existing drugs to treat other diseases.
- One Stanford startup, NuMedii, uses computational analysis of biomedical data to match existing drugs to new disease applications, winning their first contract with a pharmaceutical company.
- Continued mining of both existing and new biomedical data repositories has potential to revolutionize drug development and discovery of new
Open in order to ensure healthy lives - OpenCon UN 2018Natalia Norori
Open in order to ensure healthy lives and promote well-being for all at all ages - OpenCon United Nations Headquarters 2018 slides - Natalia Norori
CC BY 2018
MseqDR consortium: a grass-roots effort to establish a global resource aimed ...Human Variome Project
The success of whole exome sequencing (WES) for highly heterogeneous disorders, such as mitochondrial disease, is limited by substantial technical and bioinformatics challenges to correctly identify and prioritize the extensive number of sequence variants present in each patient. The likelihood of success can be greatly improved if a large cohort of patient data is assembled in which sequence variants can be systematically analysed, annotated, and interpreted relative to known phenotype. This effort has engaged and united more than 100 international mitochondrial clinicians, researchers, and bioinformaticians in the Mitochondrial Disease Sequence Data Resource (MSeqDR) consortium that formed in June 2012 to identify and prioritize the specific WES data analysis needs of the global mitochondrial disease community. Through regular web-based meetings, we have familiarized ourselves with existing strengths and gaps facing integration of MSeqDR with public resources, as well as the major practical, technical, and ethical challenges that must be overcome to create a sustainable data resource. We have now moved forward toward our common goal by establishing a central data resource (http://mseqdr.org/) that has both public access and secure web-based features that allow the coherent compilation, organization, annotation, and analysis of WES and mtDNA genome data sets generated in both clinical- and research-based settings of suspected mitochondrial disease patients. The most important aims of the MSeqDR consortium are summarized in the MSeqDR portal within the Consortium overview sections. Consortium participants are organized in 3 working groups that include (1) Technology and Bioinformatics; (2) Phenotyping, databasing, IRB concerns and access; and (3) Mitochondrial DNA specific concerns. The online MSeqDR resource is organized into discrete sections to facilitate data deposition and common reannotation, data visualization, data set mining, and access management. With the support of the United Mitochondrial Disease Foundation (UMDF) and the NINDS/NICHD U54 supported North American Mitochondrial Disease Consortium (NAMDC), the MSeqDR prototype has been built. Current major components include common data upload and reannotation using a novel HBCR based annotation tool that has also been made publicly available through the website, MSeqDR GBrowse that allows ready visualization of all public and MSeqDR specific data including labspecific aggregate data visualization tracks, MSeqDR-LSDB instance of nearly 1250 mitochondrial disease and mitochodnrial localized genes that is based on the Locus Specific Database model, exome data set mining in individuals or families using the GEM.app tool, and Account & Access Management. Within MSeqDR GBrowse it is now possible to explore data derived from MitoMap, HmtDB, ClinVar, UCSC-NumtS, ENCODE, 1000 genomes, and many other resources that bioinformaticians recruited to the project are organizing.
Genetics is becoming more personalized with direct-to-consumer genetic testing services like 23andMe. 23andMe analyzes customers' DNA samples and provides information about their ancestry, traits, and disease risks through an online platform. This empowers individuals and facilitates research by creating a large participant network. While challenges remain in fully engaging all stakeholders, personalized genetics has the potential to transform healthcare by better targeting treatment to individual genetics.
Genomic sequencing will soon be as routine as a blood test, allowing people to learn more about their genetic identity and how it relates to health conditions and treatment. However, without proper ethical guidelines, profit-driven research may not prioritize diseases that affect the most people. To address this, the public needs to be actively involved in all stages of genomics research to help shape priorities. One proposal is a "Wiki-genome" platform where people can voluntarily upload and share their genome data to help researchers, while also participating in discussions to guide future research. However, ensuring public participation will require addressing issues around privacy, informed consent, and who pays for sequencing.
Festival of Genomics 2016 London: Challenges of Big Medical Data?Matthieu Schapranow
This presentation covers the "Challenges of Big Medical Data" presentation of the 2016 Festival of Genomics workshop "Big Medical Data in Precision Medicine: Challenges or Opportunities?" on Jan 19, 2016 in London.
With recent advances in Healthcare, Personalized medicine has become a buzzword. The customization of health care, based on DNA sequencing, patient's environmental information, can lead to more efficient treatments.
By integrating various sources of data, personalized medicine improves all aspects of healthcare from prevention to monitoring.
Searching for Clinical Trials using clinicaltrials.gov and specialized search
engines
Rob Camp goes through various online tools and search engines which enable
patients to search for clinical trials. Rob’s background includes serving as
Executive Director of the EATG (European AIDS Treatment Group), the creation
of an HIV organisation in Barcelona, the creation of national groups in Spain
and other countries (organising seminars on how to create organisations in EU
Eastern States, Southern States), leading projects supported by the European
Commission department for Public Health (DG SANCO), working on funding for
NGOs. Rob is currently working half time in the US as liaison between patient
organisations and the FDA, and spends the rest of his time in Europe. Rob
speaks English and Spanish
Presentation "The Impact of All Data on Healthcare"
Keith Perry
Associate VP & Deputy CIO
UT MD Anderson Cancer Center
With continuing advancement in both technology and medicine, the drive is on to make all data meaningful to drive medical discovery and create actionable outcomes. With tools and capabilities to capture more data than ever before, the challenge becomes linking existing structured and unstructured clinical data with genomic data to increase the industry’s analytical footprint.
Learning Objectives:
∙ Discuss the need to make all data meaningful in order to speed discovery of new knowledge
∙ Provide examples of an analytical direction that supports evolution in medicine
∙ Expose the challenges facing the industry with respect to ~omits
20160811 Big Data for Health and MedicineBrian Bot
This document summarizes Brian Bot's presentation on biomedical research in an increasingly digital world. It discusses how biomedical data is increasingly being produced, aggregated, and shared digitally. Only a small percentage of studies can be fully reproduced due to issues with data availability and documentation. However, organizations like Sage Bionetworks are working to promote open sharing of complex biological data through diverse collaborations and by empowering citizens to contribute their own health data to research. One example is the mPower study on Parkinson's disease which has involved thousands of participants sharing passive and active data through mobile apps.
This document outlines Atul Butte's conflicts of interest and support network. It lists his advisory roles and consulting for various pharmaceutical and technology companies. It also lists the research collaborations and institutional support he receives from UCSF, NIH, and other foundations. The document emphasizes building the strongest team in medical data analytics to predict disease, explain rare conditions, find new drugs, and ensure the right care for patients through analyzing large biomedical datasets.
This document discusses how analyzing the large amounts of data being generated from biomedical research can help discover new drugs and diagnostics. Specifically:
- There are now over 300 billion points of data available from sources like gene expression studies and clinical trials. This amount doubles every few years.
- By analyzing relationships within this large biomedical data, researchers have already identified new uses for existing drugs to treat other diseases.
- One Stanford startup, NuMedii, uses computational analysis of biomedical data to match existing drugs to new disease applications, winning their first contract with a pharmaceutical company.
- Continued mining of both existing and new biomedical data repositories has potential to revolutionize drug development and discovery of new
Open in order to ensure healthy lives - OpenCon UN 2018Natalia Norori
Open in order to ensure healthy lives and promote well-being for all at all ages - OpenCon United Nations Headquarters 2018 slides - Natalia Norori
CC BY 2018
MseqDR consortium: a grass-roots effort to establish a global resource aimed ...Human Variome Project
The success of whole exome sequencing (WES) for highly heterogeneous disorders, such as mitochondrial disease, is limited by substantial technical and bioinformatics challenges to correctly identify and prioritize the extensive number of sequence variants present in each patient. The likelihood of success can be greatly improved if a large cohort of patient data is assembled in which sequence variants can be systematically analysed, annotated, and interpreted relative to known phenotype. This effort has engaged and united more than 100 international mitochondrial clinicians, researchers, and bioinformaticians in the Mitochondrial Disease Sequence Data Resource (MSeqDR) consortium that formed in June 2012 to identify and prioritize the specific WES data analysis needs of the global mitochondrial disease community. Through regular web-based meetings, we have familiarized ourselves with existing strengths and gaps facing integration of MSeqDR with public resources, as well as the major practical, technical, and ethical challenges that must be overcome to create a sustainable data resource. We have now moved forward toward our common goal by establishing a central data resource (http://mseqdr.org/) that has both public access and secure web-based features that allow the coherent compilation, organization, annotation, and analysis of WES and mtDNA genome data sets generated in both clinical- and research-based settings of suspected mitochondrial disease patients. The most important aims of the MSeqDR consortium are summarized in the MSeqDR portal within the Consortium overview sections. Consortium participants are organized in 3 working groups that include (1) Technology and Bioinformatics; (2) Phenotyping, databasing, IRB concerns and access; and (3) Mitochondrial DNA specific concerns. The online MSeqDR resource is organized into discrete sections to facilitate data deposition and common reannotation, data visualization, data set mining, and access management. With the support of the United Mitochondrial Disease Foundation (UMDF) and the NINDS/NICHD U54 supported North American Mitochondrial Disease Consortium (NAMDC), the MSeqDR prototype has been built. Current major components include common data upload and reannotation using a novel HBCR based annotation tool that has also been made publicly available through the website, MSeqDR GBrowse that allows ready visualization of all public and MSeqDR specific data including labspecific aggregate data visualization tracks, MSeqDR-LSDB instance of nearly 1250 mitochondrial disease and mitochodnrial localized genes that is based on the Locus Specific Database model, exome data set mining in individuals or families using the GEM.app tool, and Account & Access Management. Within MSeqDR GBrowse it is now possible to explore data derived from MitoMap, HmtDB, ClinVar, UCSC-NumtS, ENCODE, 1000 genomes, and many other resources that bioinformaticians recruited to the project are organizing.
Genetics is becoming more personalized with direct-to-consumer genetic testing services like 23andMe. 23andMe analyzes customers' DNA samples and provides information about their ancestry, traits, and disease risks through an online platform. This empowers individuals and facilitates research by creating a large participant network. While challenges remain in fully engaging all stakeholders, personalized genetics has the potential to transform healthcare by better targeting treatment to individual genetics.
Genomic sequencing will soon be as routine as a blood test, allowing people to learn more about their genetic identity and how it relates to health conditions and treatment. However, without proper ethical guidelines, profit-driven research may not prioritize diseases that affect the most people. To address this, the public needs to be actively involved in all stages of genomics research to help shape priorities. One proposal is a "Wiki-genome" platform where people can voluntarily upload and share their genome data to help researchers, while also participating in discussions to guide future research. However, ensuring public participation will require addressing issues around privacy, informed consent, and who pays for sequencing.
PERSONALISED MEDICINE: Use of Personalised Medicine in the prevention of disease and the maintenance of wellness
THE ENIGMA OF THE THRACIANS AND THE ORPHEUS MYTH: Journey to the Past Orphic Mysteries
, AND THE LORD OF THE NIGHT SKY: Observe top spring objects with a robotic telescope from home
The document discusses personalized medicine and the company 23andMe. It provides definitions of personalized medicine from various sources emphasizing using genetic information to prevent and treat disease. It outlines the history of genomics projects like the Human Genome Project and HapMap. 23andMe allows customers to learn about their genetics through direct-to-consumer genetic testing. Customers submit a saliva sample and access results online regarding ancestry, traits, and disease risks. 23andMe aims to empower individuals and facilitate research through participant-driven studies. The document discusses examples of genetic insights into conditions like cancer and how pharmacogenetics can guide treatment choices.
This document discusses using information and communication technologies (ICT) to support global biomedical research infrastructure. It outlines:
1) How new data types from areas like genomics and nanomedicine are being generated at unprecedented scales and need to be collected, integrated and analyzed using distributed computing.
2) Issues around using electronic health records and research data to model human physiology and disease.
3) Participants in the discussion including experts from Microsoft, Spanish and Belgian universities who will discuss using ICT to advance personalized and genomic medicine.
Scott Edmunds from GigaScience on 'Publishing in the Open Data Era", at the "Open, Crowdsource and Blockchain Science!" hangout at Hackerspace.sg, 23rd March 2015
This document provides information about the "BioData World West 2017" conference taking place April 26-27, 2017 in San Francisco. The conference will bring together over 200 participants from various backgrounds to discuss disruptive approaches in drug development, personalized medicine, and clinical applications using big data in precision medicine. Expert speakers will present on topics including genomics, precision medicine, and a new AI track in partnership with Merck. Registering online reserves a place at the conference and featured sessions will explore various applications and challenges of harnessing big data in healthcare and biomedicine.
Univ of Miami CTSI: Citizen science seminar; Oct 2014Richard Bookman
The University of Miami's Clinical & Translational Science Institute runs a seminar course for MS students.
This talk surveys 8 citizen science projects, reviews NIH's current activities, and identifies issues for attention, particularly with ethical, legal and social implications.
This document summarizes the results of a genetic genealogy study of the Zitting surname. It finds that:
1) The Zitting males in the study belong to the R1a Y-DNA haplogroup, and more specifically the R1a1a1b1a2a subgroup, as predicted by an expert.
2) Americans with the Zitting surname also belong to the R1a haplogroup, with defining SNPs of M198 and M17.
3) The distribution of the rare R1a1a1b1a2a subgroup is examined, finding matches in other populations.
4) Autosomal DNA results for one individual are shown as an
The document discusses direct-to-consumer genetic testing services. It lists over 30 companies that offer such DNA tests covering ancestry, ethnicity, health, and other areas. The four largest companies - Family Tree DNA, 23andMe, Ancestry, and National Geographic - are highlighted. Business models for consumer genetic services are reviewed. Tools for self-analysis of DNA data like Promethease and SNPedia are presented. Research on the ethics of these direct-to-consumer tests is cited, and some ethical questions raised are ownership of genetic data, privacy, and informed consent.
Marja Pirttivaara gave a presentation on bridging social media and DNA at the Family Tree DNA 9th Genetic Genealogy Conference in Houston on November 10, 2013. She discussed how Finns have a strong presence in DNA due to Finland's unique population structure, migration history, and world-class genetic research. She also outlined how Finns actively use social media like Facebook, forums, blogs and Twitter for genetic genealogy networking, and provided tips on privacy, intellectual property and integrating social media platforms.
1.) Introduction
Our Movement is not new; it is the same as it was for Freedom, Justice, and Equality since we were labeled as slaves. However, this movement at its core must entail economics.
2.) Historical Context
This is the same movement because none of the previous movements, such as boycotts, were ever completed. For some, maybe, but for the most part, it’s just a place to keep your stable until you’re ready to assimilate them into your system. The rest of the crabs are left in the world’s worst parts, begging for scraps.
3.) Economic Empowerment
Our Movement aims to show that it is indeed possible for the less fortunate to establish their economic system. Everyone else – Caucasian, Asian, Mexican, Israeli, Jews, etc. – has their systems, and they all set up and usurp money from the less fortunate. So, the less fortunate buy from every one of them, yet none of them buy from the less fortunate. Moreover, the less fortunate really don’t have anything to sell.
4.) Collaboration with Organizations
Our Movement will demonstrate how organizations such as the National Association for the Advancement of Colored People, National Urban League, Black Lives Matter, and others can assist in creating a much more indestructible Black Wall Street.
5.) Vision for the Future
Our Movement will not settle for less than those who came before us and stopped before the rights were equal. The economy, jobs, healthcare, education, housing, incarceration – everything is unfair, and what isn’t is rigged for the less fortunate to fail, as evidenced in society.
6.) Call to Action
Our movement has started and implemented everything needed for the advancement of the economic system. There are positions for only those who understand the importance of this movement, as failure to address it will continue the degradation of the people deemed less fortunate.
No, this isn’t Noah’s Ark, nor am I a Prophet. I’m just a man who wrote a couple of books, created a magnificent website: http://www.thearkproject.llc, and who truly hopes to try and initiate a truly sustainable economic system for deprived people. We may not all have the same beliefs, but if our methods are tried, tested, and proven, we can come together and help others. My website: http://www.thearkproject.llc is very informative and considerably controversial. Please check it out, and if you are afraid, leave immediately; it’s no place for cowards. The last Prophet said: “Whoever among you sees an evil action, then let him change it with his hand [by taking action]; if he cannot, then with his tongue [by speaking out]; and if he cannot, then, with his heart – and that is the weakest of faith.” [Sahih Muslim] If we all, or even some of us, did this, there would be significant change. We are able to witness it on small and grand scales, for example, from climate control to business partnerships. I encourage, invite, and challenge you all to support me by visiting my website.
Why Psychological Safety Matters for Software Teams - ACE 2024 - Ben Linders.pdfBen Linders
Psychological safety in teams is important; team members must feel safe and able to communicate and collaborate effectively to deliver value. It’s also necessary to build long-lasting teams since things will happen and relationships will be strained.
But, how safe is a team? How can we determine if there are any factors that make the team unsafe or have an impact on the team’s culture?
In this mini-workshop, we’ll play games for psychological safety and team culture utilizing a deck of coaching cards, The Psychological Safety Cards. We will learn how to use gamification to gain a better understanding of what’s going on in teams. Individuals share what they have learned from working in teams, what has impacted the team’s safety and culture, and what has led to positive change.
Different game formats will be played in groups in parallel. Examples are an ice-breaker to get people talking about psychological safety, a constellation where people take positions about aspects of psychological safety in their team or organization, and collaborative card games where people work together to create an environment that fosters psychological safety.
This presentation by Professor Giuseppe Colangelo, Jean Monnet Professor of European Innovation Policy, was made during the discussion “The Intersection between Competition and Data Privacy” held at the 143rd meeting of the OECD Competition Committee on 13 June 2024. More papers and presentations on the topic can be found at oe.cd/ibcdp.
This presentation was uploaded with the author’s consent.
This presentation by OECD, OECD Secretariat, was made during the discussion “The Intersection between Competition and Data Privacy” held at the 143rd meeting of the OECD Competition Committee on 13 June 2024. More papers and presentations on the topic can be found at oe.cd/ibcdp.
This presentation was uploaded with the author’s consent.
The importance of sustainable and efficient computational practices in artificial intelligence (AI) and deep learning has become increasingly critical. This webinar focuses on the intersection of sustainability and AI, highlighting the significance of energy-efficient deep learning, innovative randomization techniques in neural networks, the potential of reservoir computing, and the cutting-edge realm of neuromorphic computing. This webinar aims to connect theoretical knowledge with practical applications and provide insights into how these innovative approaches can lead to more robust, efficient, and environmentally conscious AI systems.
Webinar Speaker: Prof. Claudio Gallicchio, Assistant Professor, University of Pisa
Claudio Gallicchio is an Assistant Professor at the Department of Computer Science of the University of Pisa, Italy. His research involves merging concepts from Deep Learning, Dynamical Systems, and Randomized Neural Systems, and he has co-authored over 100 scientific publications on the subject. He is the founder of the IEEE CIS Task Force on Reservoir Computing, and the co-founder and chair of the IEEE Task Force on Randomization-based Neural Networks and Learning Systems. He is an associate editor of IEEE Transactions on Neural Networks and Learning Systems (TNNLS).
• For a full set of 530+ questions. Go to
https://skillcertpro.com/product/servicenow-cis-itsm-exam-questions/
• SkillCertPro offers detailed explanations to each question which helps to understand the concepts better.
• It is recommended to score above 85% in SkillCertPro exams before attempting a real exam.
• SkillCertPro updates exam questions every 2 weeks.
• You will get life time access and life time free updates
• SkillCertPro assures 100% pass guarantee in first attempt.
This presentation by Tim Capel, Director of the UK Information Commissioner’s Office Legal Service, was made during the discussion “The Intersection between Competition and Data Privacy” held at the 143rd meeting of the OECD Competition Committee on 13 June 2024. More papers and presentations on the topic can be found at oe.cd/ibcdp.
This presentation was uploaded with the author’s consent.
This presentation by Katharine Kemp, Associate Professor at the Faculty of Law & Justice at UNSW Sydney, was made during the discussion “The Intersection between Competition and Data Privacy” held at the 143rd meeting of the OECD Competition Committee on 13 June 2024. More papers and presentations on the topic can be found at oe.cd/ibcdp.
This presentation was uploaded with the author’s consent.
Gamify it until you make it Improving Agile Development and Operations with ...Ben Linders
So many challenges, so little time. While we’re busy developing software and keeping it operational, we also need to sharpen the saw, but how? Gamification can be a way to look at how you’re doing and find out where to improve. It’s a great way to have everyone involved and get the best out of people.
In this presentation, Ben Linders will show how playing games with the DevOps coaching cards can help to explore your current development and deployment (DevOps) practices and decide as a team what to improve or experiment with.
The games that we play are based on an engagement model. Instead of imposing change, the games enable people to pull in ideas for change and apply those in a way that best suits their collective needs.
By playing games, you can learn from each other. Teams can use games, exercises, and coaching cards to discuss values, principles, and practices, and share their experiences and learnings.
Different game formats can be used to share experiences on DevOps principles and practices and explore how they can be applied effectively. This presentation provides an overview of playing formats and will inspire you to come up with your own formats.
Legislation And Regulations For Import, Manufacture,.pptx
Open human genome data
1. Open human genome data
Open up! – Open Data and Open Access
Annual TKT/CLIDP Symposium
University of Turku, 13th May, 2016
Marja Pirttivaara, PhD, MBA (social and healthcare management)
3. Human genome: abt 3 billion pairs of nucleotides.
Variants are Single Nucleotide Polymorphisms, SNPs.
Basics of genome and cost of sequencing
Wetterstrand KA. DNA Sequencing Costs: Data from the NHGRI Genome Sequencing
Program (GSP) Available at: www.genome.gov/sequencingcosts. Accessed 13th May, 2016.
13th May, 2016, Marja Pirttivaara
4. Human genome – human evolution
“The human genome is contained in chromosomes that are present in almost
every cell in our bodies. It is composed of approximately 3.2 billion
nucleotides. When cells replicate to form germ cells that will contribute to
the next generation, mutations occur. As a result of these mutations,
about 50 to 200 new substitutions exist in every new individual that
is born. These substitutions accumulate in the genome over time to the
extent that roughly one nucleotide in a thousand differs between two human
genomes today, whereas roughly one nucleotide in a hundred differs
between a human and a chimpanzee genome. In addition, duplicated DNA
sequences differ both between individuals and between species.”
Svante Pääbo: The Contribution of Ancient Hominin Genomes from Siberia to
Our Understanding of Human Evolution, Herald of the Russian Academy of
Sciences, Vol 85 No. 5, 2015
http://www.eva.mpg.de/documents/RussianAcadSciences/Paeaebo_Contribut
ion_HeraldRussAcadSci_2015_2226501.pdf
13th May, 2016, Marja Pirttivaara
6. • KardioKompassi is FIMM’s first preventative health care pilot project utilizing
personal genetic risk information and returning it to the participants.
• Cardio-vascular diseases, appr. 50 snips chosen.
• Partners: FIMM, Finnish Red Cross Blood Services and the Finnish Innovation
Fund Sitra.
• Aim: study the ways of providing people with health-risk information based on
genetic research data, the ways this information is used in preventive
healthcare and its usefulness with respect to individual health behaviour.
• In this project, the transfer of genetic information to an individual’s personal
online health account was also being tested for the first time in Finland.
• The application developed during the project is further developed and utilized
in new research projects.
Kardiokompassi – unique Finnish pilot
Marja Pirttivaara, 13th May 2016
7. “Many, many more individuals will have to make their personal genomes publicly
available before we begin to get a real feeling of where we want to go.”
"I am homozygous for the “10” variant of the P450 drug metabolizing gene,
CYP2P6 . As a result, I metabolize beta-blockers much more slowly than most
other Caucasians. Before I take this knowledge, my use of beta-blockers to
control my blood pressure caused me to constantly fall asleep at inappropriate
moments. Instead of a daily pill, I now take one every week….”
James Watson: Living with my personal
genome
Ref:http://www.futuremedicine.com/doi/pdf/10.2217/pme.09.62
Picture: http://www.fraxa.org/fraxa/advisors/
Marja Pirttivaara 13th May 2016
8. 8
Open data, open science, mydata,
big data, big science, open tools – and open minds
The Opportunity Project in the US
“..they've challenged the nation to ask not
what your country can code for you, but
ask what you can code for your country.” …
What I saw at the launch of The
Opportunity Project yesterday suggested a
shift in an approach that has promise.
Instead of simply dumping a data set onto
Data.gov and challenging people to use it,
the White House worked with over 30 tech
companies and nonprofits to develop
prototypes of new tools or add features to
existing platforms…”
People
ToolsData
http://www.techrepublic.com/article/president-obamas-new-open-data-initiative-could-help-cities-help-themselves
https://www.whitehouse.gov/the-press-office/2016/03/07/fact-sheet-white-house-launches-opportunity-project-utilizing-open-data
13th May, 2016, Marja Pirttivaara
9. 9
Genome data in open databases
• Primary nucleotide sequence databases:
• GenBank (NCBI / NIH, USA)
http://www.ncbi.nlm.nih.gov/genbank/
• EMBL (European Bioinformatics Institute)
European Nucleotide Archive
http://www.ebi.ac.uk/ena
• DDBJ, DNA Data Bank of Japan (National
Institute of Genetics)
http://www.ddbj.nig.ac.jp/
• Meta databases
• Genome databases
• Protein sequence databases
• Proteomics databases
• Protein structure databases
• Protein model databases
• RNA databases
• Carbohydrate structure databases
• Protein-protein and other molecular
interactions
• Signal transduction pathway databases
• Metabolic pathway and Protein Function
databases
• Microarray databases
• Exosomal databases
• Mathematical model databases
• PCR and quantitative PCR primer databases
• Phenotype databases
• Specialized databases
• Taxonomic databases
• Wiki-style databases
• Metabolomic Databases
• ETC
13th May, 2016, Marja Pirttivaarahttps://en.wikipedia.org/wiki/List_of_biological_databases
10. 10
Biobanks
• Biobank is ”clinical samples + data +
informed consent” according to the
Finnish biobank regulation.
• Globally, biobanks will form a global
evolving network of actors and
actions: samples, labs & testing,
data storage, consents, data
sharing, tools, cooperation,
competences…
• Ethics!
“Biobank is a collection of biological
samples and data gathered with
the donor’s consent for future
medical research and product
development for healthcare and
health promotion purposes.”
“Your consent could be crucial for
the development of new medicines
and treatments. Your sample could
change the world!”
http://www.biopankki.fi/
www.genome.gov 13th May, 2016, Marja Pirttivaara
11. 11
Open data deserves open tools: tools for genome data
Autosomal DNA tools
• http://isogg.org/wiki/Autosomal_DN
A_tools
Y-DNA tools
• http://isogg.org/wiki/Y-DNA_tools
Mitochondrial DNA Tools
• http://isogg.org/wiki/MtDNA_tools
CSC Bioinformatics Tools
• https://research.csc.fi/bioscience-
programs
BLAST finds regions of similarity between
biological sequences
• http://blast.ncbi.nlm.nih.gov/Blast.cgi
BEAST Bayesian evolutionary analysis by
sampling trees (Markov Chain Monte Carlo
simulation)
• http://beast2.org/
R language
• https://www.r-project.org/
13th May, 2016, Marja Pirttivaara
12. 1213th May, 2016, Marja Pirttivaara
Philip E. Bourne: Open data in a Global Ecosystem, Nov. 2015
http://www.slideshare.net/pebourne/open-data-in-a-global-ecosystem
13. • Family Tree DNA / Gene by Gene
www.familytreedna.com
• 23andMe
www.23andme.com
• Ancestry
www.ancestry.com
• National Geographic
http://genographic.nationalgeographic.com
The Big Four in DTC
Marja Pirttivaara 13th May 2016
14. 14
Donation of mtDNA to the NIH NCBI GenBank
Marja Pirttivaara 13th May 2016http://www.ncbi.nlm.nih.gov/
15. 15
SNPedia and Promethease
• SNPedia is the Database
• Promethease is a Program to
Personalize
• Upload a file of genotypes with
dbSNP IDs and Promethease makes
a personalized report
• It uses SNPedia to find and complie
the scientific literature specific to
your DNA.
• Personal data is not stored, shared
or sold.
• http://www.snpedia.com/index.php/SNPedia
• https://www.snpedia.com/index.php/Promethease
• https://www.promethease.com/
• Antonio Regalado: How a Wiki Is Keeping Direct-to-
Consumer Genetics Alive, MIT Technology Review 2014
www.technologyreview.com/featuredstory/531461/how-
a-wiki-is-keeping-direct-to-consumer-genetics-alive/
Marja Pirttivaara 13th May 2016
Map of SNPedia usage in Finland,
thx Mike Cariaso, SNPedia
16. 16Sitra • Name • 13.5.2016 •
Example from a personalized Promethease report
17. What do people want to know?
●What will I die from? When will I die?
●What diseases am I at higher risk for, and by how much?
●What diseases might my children inherit?
●Are some drugs better than others for me? Or worse?
●Who can explain all this to me?
●Will my health-care providers understand it?
Thx to Mike Cariaso and Greg Lennon, SNPedia
Marja Pirttivaara 13th May 2016
18. Stanford course Gene 210 – Genomics and
Personalized Medicine
Marja Pirttivaara 13th May 2016
Course includes analysis of own DTC genome data and SNPedia writing
http://web. stanford.edu/class/gene210/web/html/welcome.html
http://www.snpedia.com/index.php/Rs1800497
19. 19
National Genome Strategy: Improving health through
the use of genomic data
Marja Pirttivaara 13th May 2016http://stm.fi/en/genomicdata
20. • Who owns the data?
• Who can use the data?
• Informed consent
• Trust
• Transparency
• Incidental findings
• Right to know and right not to know.
20
Privacy and ethics
13th May, 2016, Marja Pirttivaara
www.genome.gov
21. New cooperation, new cultures, new skills,
new methodologies, new tools, new emphasis,
new modes of discovery...
New era
Marja Pirttivaara 13th May 2016www.genome.gov